Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line

scientific article published on 22 March 2019

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3390/VACCINES7010033
P932PMC publication ID6466103
P698PubMed publication ID30909516

P50authorAdrian V. S. HillQ22278197
Sarah GilbertQ30513802
Katie J. EwerQ55175778
Pedro M FolegattiQ56380092
Amy FlaxmanQ57433031
Angela MinassianQ62748527
Duncan BellamyQ91783422
Ian PoultonQ91783430
Fernando Ramos LopezQ92605172
Alison M. LawrieQ109926029
Celia H MittonQ114367905
P2093author name stringRachel Roberts
Chris Ellis
Thomas G Evans
Megan Baker
Catherine Mair
Raquel L Ramon
P2860cites workCellular immune correlates of protection against symptomatic pandemic influenza.Q30353819
Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort StudyQ30373419
Influenza vaccine supply, 2005-2006: did we come up short?Q33283742
Efficacy of high-dose versus standard-dose influenza vaccine in older adultsQ34433416
Efficacy and effectiveness of influenza vaccines in elderly people: a systematic reviewQ34455910
A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 yearsQ34464975
Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.Q34699088
Reverse transcriptase activity in chicken embryo fibroblast culture supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNAQ35880984
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humansQ36014866
Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern ItalyQ36248959
Homology between avian oncornavirus RNAs and DNA from several avian speciesQ36569406
Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responsesQ37690439
Recombinant MVA vaccines: dispelling the mythsQ38092468
Immunosenescence: Influenza vaccination and the elderlyQ38207437
Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studiesQ38803189
Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vectorQ39592790
New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagationQ39837248
An avian cell line designed for production of highly attenuated virusesQ39906835
Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or OlderQ40151067
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trialQ42687156
A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine.Q45778868
Estimates of global seasonal influenza-associated respiratory mortality: a modelling studyQ46876629
Vaccines for preventing influenza in the elderly.Q47641366
Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture.Q50308620
Novel Platforms for the Development of a Universal Influenza Vaccine.Q52599675
Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine.Q54247364
Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults.Q55047600
Economic burden of seasonal influenza in the United StatesQ56659921
The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderlyQ87232318
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectinfectious diseaseQ18123741
drug discoveryQ1418791
immunologyQ101929
Viral VectorsQ57983034
P304page(s)33
P577publication date2019-03-22
P1433published inVaccinesQ27725508
P1476titleSafety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
P478volume7

Reverse relations

cites work (P2860)
Q89723360Next-generation influenza vaccines: opportunities and challenges
Q93180887Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Search more.